PE20040190A1 - Tiazoles y oxazoles sustituidos que modulan la actividad de ppar - Google Patents

Tiazoles y oxazoles sustituidos que modulan la actividad de ppar

Info

Publication number
PE20040190A1
PE20040190A1 PE2003000213A PE2003000213A PE20040190A1 PE 20040190 A1 PE20040190 A1 PE 20040190A1 PE 2003000213 A PE2003000213 A PE 2003000213A PE 2003000213 A PE2003000213 A PE 2003000213A PE 20040190 A1 PE20040190 A1 PE 20040190A1
Authority
PE
Peru
Prior art keywords
alkyl
aryl
members
forming
ring
Prior art date
Application number
PE2003000213A
Other languages
English (en)
Inventor
xue-ming Cheng
Gary Frederick Filzen
Bharat Kalidas Trivedi
Chitase Lee
Andrew George Geyer
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20040190A1 publication Critical patent/PE20040190A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS TIAZOLES Y OXAZOLES SUSTITUIDOS DE LA FORMULA I DONDE V1 ES UNA CADENA DE HIDROCARBUROS QUE PUEDE TENER HETEROATOMOS DE 3-6 ATOMOS, EN LA QUE EL C1 ESTA CONECTADO AL C2, FORMANDO UN ANILLO DE 5-8 MIEMBROS DONDE -X2-(CH2)n-CO2, ESTA COMO SUSTITUYENTE; X0 Y X1 ES O O S; X2 ES O, S, NR4 O ESTA AUSENTE; Ar1 ES ARILO O HETEROARILO; R1,R2,R3 ES H, ALQUILO INFERIOR, ALCOXI INFERIOR, TIOALCOXI INFERIOR, -O(CH2)pCF3, HALOGENO, NITRO, CIANO, -OH, -SH, CF3, S(O)pARILO, -(CH2)mOR4, -CH2)mNR5R6, ENTRE OTROS, O R1 Y R2 ESTAN UNIDAS FORMANDO UN ANILLO HETEROCICLOALQUILICO O CICLOALQUILICO; R4 ES H, ALQUILO, ALQUENILO, ALQUINILO O ARILO; R5 Y R6 SON H, ALQUILO, ALQUENILO, ALQUINILO, CICLOALQUILO, SO2 ALQUILO O SO2 ARILO, O ESTAN UNIDOS FORMANDO UN ANILLO DE 4-7 MIEMBROS CON 0-3 HETEROATOMOS; m ES 0-5; n ES 0-5 Y p ES 0-2. SON COMPUESTOS PREFERIDOS: ACIDO 5-[4-METIL-2-(4-TRIFLUOROMETIL-FENIL)-TIAZOL-5-ILMETILSULFANIL]-INDAN-2-CARBOXILICO, ACIDO {5-[4-METIL-2-(4-TRIFLUOROMETIL-FENIL)-TIAZOL-5-ILMETILSULFANIL]-INDAN-2-IL}-ACETICO,ENTRE OTROS.TAMBIEN SE REFIERE A METODOS PARA PREPARACION.SON COMPUESTOS QUE MODULAN LA ACTIVIDAD DE PPAR Y SE PUEDEN USAR PARA TRATAR, PREVENIR O CONTROLAR LA OBESIDAD, HIPERGLICEMIA, HIPERLIPIDEMIA, ARTEROSCLEROSIS, HIPERINSULINEMIA Y DIABETES MELLITUS NO DEPENDIENTE DE INSULINA
PE2003000213A 2002-03-07 2003-03-05 Tiazoles y oxazoles sustituidos que modulan la actividad de ppar PE20040190A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36241102P 2002-03-07 2002-03-07

Publications (1)

Publication Number Publication Date
PE20040190A1 true PE20040190A1 (es) 2004-03-20

Family

ID=27789158

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000213A PE20040190A1 (es) 2002-03-07 2003-03-05 Tiazoles y oxazoles sustituidos que modulan la actividad de ppar

Country Status (15)

Country Link
US (3) US6867224B2 (es)
EP (1) EP1480641A1 (es)
JP (1) JP2005527509A (es)
AR (1) AR038882A1 (es)
AU (1) AU2003207914A1 (es)
BR (1) BR0308202A (es)
CA (1) CA2478164A1 (es)
GT (1) GT200300054A (es)
MX (1) MXPA04008627A (es)
NI (1) NI200300039A (es)
PA (1) PA8568601A1 (es)
PE (1) PE20040190A1 (es)
TW (1) TW200405812A (es)
UY (1) UY27696A1 (es)
WO (1) WO2003074051A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04003398A (es) * 2001-10-12 2004-11-22 Nippon Chemiphar Co Activador para el receptor o activado con el proliferador de peroxisoma.
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
AU2003303681A1 (en) * 2003-01-06 2004-08-10 Eli Lilly And Company Fused heterocyclic derivates as ppar modulators
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
RU2344135C2 (ru) * 2003-07-02 2009-01-20 Ф.Хоффманн-Ля Рош Аг Тиазолзамещенные индолилпроизводные и их применение в качестве модуляторов ppar
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7728155B2 (en) 2003-10-24 2010-06-01 Wyeth Llc Dihydrobenzofuranyl alkanamines and methods for using same as cns agents
RU2367659C2 (ru) * 2003-11-05 2009-09-20 Ф.Хоффманн-Ля Рош Аг Гетероарильные производные в качестве активаторов рецепторов, активируемых пролифераторами пероксисом (ppar)
WO2005060958A1 (en) * 2003-12-19 2005-07-07 Kalypsys, Inc. (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes
KR100802864B1 (ko) * 2004-03-09 2008-02-12 에프. 호프만-라 로슈 아게 Ｐｐａｒ 활성화제로서 피라졸릴 인돌릴 유도체
CA2557789C (en) * 2004-03-09 2012-12-11 F.Hoffmann-La Roche Ag Pyrazolyl indolyl derivatives as ppar activators
DE602005024384D1 (de) 2004-05-05 2010-12-09 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
US20060014785A1 (en) * 2004-05-25 2006-01-19 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
AU2005247473A1 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
US7405236B2 (en) * 2004-08-16 2008-07-29 Hoffman-La Roche Inc. Indole derivatives comprising an acetylene group
US20080096916A1 (en) * 2004-11-18 2008-04-24 Pfizer Inc. Drugs And Prodrugs Useful The Treatment Of Energy Balance In Ruminants
RU2416601C2 (ru) * 2005-02-25 2011-04-20 Оно Фармасьютикал Ко., Лтд. Соединение индола и его применение
ES2372617T3 (es) 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de ppar-delta.
CN103224477A (zh) 2005-12-22 2013-07-31 高点制药有限责任公司 作为PPAR-δ活化剂的苯氧基乙酸
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
US8202686B2 (en) * 2007-03-22 2012-06-19 Advanced Liquid Logic, Inc. Enzyme assays for a droplet actuator
TW200927740A (en) * 2007-11-13 2009-07-01 Bial Portela & Ca Sa Process
TWI469965B (zh) 2008-12-22 2015-01-21 Ono Pharmaceutical Co 乙炔基吲哚化合物
EP2516669B1 (en) 2009-12-21 2016-10-12 Advanced Liquid Logic, Inc. Enzyme assays on a droplet actuator
AR080374A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparcion de 2-(ciclohexilmetil)-n-(2-((2s)-1-metilpirrolidin-2-il) etil)- 1,2,3,4-tetrahidroisoquinolin-7- sulfonamida
CA2803159A1 (en) 2010-06-21 2011-12-29 Ono Pharmaceutical Co., Ltd. New crystalline forms of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1h-indole-1,3-diyl]dibutanoic acid, 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1h-indole-1,3-diyl]dibutanoic acid, and 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl}ethynyl)-1h-indole-1,3-diyl]dibutano
WO2013009927A2 (en) 2011-07-11 2013-01-17 Advanced Liquid Logic, Inc. Droplet actuators and techniques for droplet-based assays
JP6106179B2 (ja) * 2012-02-24 2017-03-29 武田薬品工業株式会社 芳香環化合物
EP3756661A1 (en) 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy
CN109071435A (zh) * 2016-01-21 2018-12-21 耶路撒冷希伯来大学伊森姆研究发展公司 吲哚啉衍生物、包含它们的组合物及其用途
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
DE60005973T2 (de) 1999-08-27 2004-05-13 Eli Lilly And Co., Indianapolis Biaryl-oxa(thia)zolderivate und ihre verwendung als ppars modulatoren
US6639077B2 (en) * 2000-03-23 2003-10-28 Merck Frosst Canada & Co. Tri-aryl-substituted-ethane PDE4 inhibitors
AU2001268162A1 (en) 2000-06-02 2001-12-17 Cor Therapeutics, Inc. Methods for producing chiral chromones, chromanes, amino substituted chromanes and intermediates therefor
US6903227B2 (en) 2000-06-02 2005-06-07 Millennium Pharmaceuticals, Inc. Synthesis of 2-acyl substituted chromanes and intermediates thereof
DE60129712T2 (de) 2000-08-23 2008-07-03 Eli Lilly And Co., Indianapolis Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
HUP0300857A3 (en) 2000-08-23 2007-03-28 Lilly Co Eli Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
CA2448639A1 (en) 2001-05-29 2002-12-05 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic derivatives and medicinal use thereof
EA200400011A1 (ru) 2001-06-07 2004-06-24 Эли Лилли Энд Компани Модуляторы рецепторов, активируемых пролифераторами пероксисом (prar)
ATE394376T1 (de) 2001-06-18 2008-05-15 Ono Pharmaceutical Co Tetrahydrochinolinderivatverbindung und die verbindung als wirkstoff enthaltendes arzneimittel
AR036237A1 (es) 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
US6833380B2 (en) * 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation

Also Published As

Publication number Publication date
NI200300039A (es) 2005-09-21
US6867224B2 (en) 2005-03-15
US20050107442A1 (en) 2005-05-19
AU2003207914A1 (en) 2003-09-16
JP2005527509A (ja) 2005-09-15
CA2478164A1 (en) 2003-09-12
TW200405812A (en) 2004-04-16
BR0308202A (pt) 2004-12-21
AR038882A1 (es) 2005-02-02
GT200300054A (es) 2003-10-10
US20050113422A1 (en) 2005-05-26
WO2003074051A1 (en) 2003-09-12
UY27696A1 (es) 2003-10-31
EP1480641A1 (en) 2004-12-01
US7109222B2 (en) 2006-09-19
PA8568601A1 (es) 2003-11-12
MXPA04008627A (es) 2004-12-06
US20030207915A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
PE20040190A1 (es) Tiazoles y oxazoles sustituidos que modulan la actividad de ppar
PE20031010A1 (es) Derivados de tiazol y oxazol que modulan la actividad de ppar
PE20020100A1 (es) DERIVADOS DE 2-SULFONIL AMINO-1,3-TIAZOL COMO INHIBIDORES DE 11-ß-HIDROXI ESTEROIDE DESHIDROGENASA TIPO 1 (11ßHSD1)
PE20030989A1 (es) Derivados de tiazol y oxazol que modulan la actividad de ppar
PE20011313A1 (es) Activadores de glucoquinasa que contienen hidantoina
PE20001590A1 (es) Compuestos heterociclicos, aromaticos utiles como secretagogos de la hormona del crecimiento
PE20050417A1 (es) Compuestos que modulan la actividad de ppar y procedimientos de preparacion
PE20040801A1 (es) Derivados de pirazina y piridina 5-sustituidos como activadores de glucoquinasa
PE20021152A1 (es) Derivados de oxazol como agonistas de receptores activados por proliferacion de peroxisoma
CR11263A (es) COMPUESTOS NOVEDOSOS QUE POSEEN ACTIVIDAD INNHIBITORIA CONTRA TRANSPORTADOR DE GLUCOSA DEPENDIENTE DE SODIO (Solicitud divisional)
PE20011010A1 (es) Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
PE20091820A1 (es) Compuestos heterociclicos con uniones puente y metodos para usarlos
PE20030326A1 (es) Derivados del acido indan acetico y su uso como agentes farmaceuticos, intermediarios y metodo de preparacion
PE20000947A1 (es) ACTIVADORES DE hPPARþ Y hPPARO
PE20010406A1 (es) ACIDO 2-{2-METIL-4[({4-METIL-2[4-(TRIFLUOROMETIL)FENIL]-1,3-TIAZOL-5-IL}METIL)SULFANIL]FENOXI}ACETICO COMO AGONISTA DEL hPPARd
PE20020667A1 (es) Derivados de piperazina como ligandos del receptor 5ht2
PE20030930A1 (es) Derivados de tiazol como antagonistas del receptor npy
PE20040307A1 (es) Compuestos que modulan la actividad ppar y procedimientos para su preparacion
PE20050121A1 (es) Acidos tienil-hidroxamicos, sustituidos referidos a la actividad enzimatica de la histona desacetilasa
AR057661A1 (es) Un derivado de oxima y sus preparaciones
PE20071094A1 (es) Derivados 1-ortoflurofenil sustituidos 1,2,5-tiadiazolidindionas como inhibidores de ptpasa
PE20011047A1 (es) Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas
PE20001467A1 (es) Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina
PE20040720A1 (es) Derivados de benzodioxol
PE20011022A1 (es) Compuestos trans olefinicos activadores glucoquinasa

Legal Events

Date Code Title Description
FD Application declared void or lapsed